The presence of continuously active and enhanced spleen tyrosine kinase (SYK) in FLT3-ITD-positive AML, its overexpression affects the transformation of AML and its resistance to FLLT3 inhibitors (107). This evidence concerns the gene SYK and acute myeloid leukemia.